E-MAIL UPDATES

Click here to join
our Electronic Communications.

Click here to view our presentations at SITC 33rd Annual Meeting SITC 2018

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Secures European Patent for Eftilagimod Alpha in Combination with Therapeutic Antibodies for Treating Cancer

November 29th 2018
press releases

Immutep Granted European Patent for Eftilagimod Alpha in Combination with a PD-1 or PD-L1 Inhibitor

November 28th 2018
press releases

New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit

November 27th 2018
press releases
more

Investor updates

Investor updates.

Investor Update - June 2018

June 19th 2018
investor updates

Investor Update - December 2017

December 21st 2017
investor updates

Investor Update Edition 21

October 1st 2017
investor updates
more

Analyst reports

Analyst reports.

Maxim - More TACTI-mel Data Presented at the Annual ICI Europe Summit

November 27th 2018
analyst reports

Edison - A big year ahead for efti

November 21st 2018
analyst reports

Maxim – Immutep Presents “efti” (LAG-3) Data at SITC Summary

November 13th 2018
analyst reports
more